194 related articles for article (PubMed ID: 22511492)
21. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Badros A; Morris C; Zangari M; Barlogie B; Tricot G
Leuk Lymphoma; 2002 Jun; 43(6):1267-71. PubMed ID: 12152995
[TBL] [Abstract][Full Text] [Related]
22. Current therapeutic uses of lenalidomide in multiple myeloma.
Hideshima T; Richardson PG; Anderson KC
Expert Opin Investig Drugs; 2006 Feb; 15(2):171-9. PubMed ID: 16433596
[TBL] [Abstract][Full Text] [Related]
23. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
24. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Usmani SZ; Sexton R; Hoering A; Heuck CJ; Nair B; Waheed S; Al Sayed Y; Chauhan N; Ahmad N; Atrash S; Petty N; van Rhee F; Crowley J; Barlogie B
Blood; 2012 Aug; 120(8):1597-600. PubMed ID: 22674807
[TBL] [Abstract][Full Text] [Related]
25. "Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
Thakral B; Wang SA
Blood; 2017 Sep; 130(13):1600. PubMed ID: 28963106
[No Abstract] [Full Text] [Related]
26. Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.
Jena RK; Swain TR; Kansurkar SS; Swain M
Eur J Clin Pharmacol; 2012 May; 68(5):881-4. PubMed ID: 22127618
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
28. Decreased neutrophil function in newly diagnosed multiple myeloma patients is restored with lenalidomide therapy.
Askman S; Westerlund J; Pettersson Å; Hellmark T; Johansson Å; Wichert S; Hansson M
Eur J Haematol; 2024 Jul; 113(1):72-81. PubMed ID: 38553844
[TBL] [Abstract][Full Text] [Related]
29. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
30. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
[TBL] [Abstract][Full Text] [Related]
31. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
[TBL] [Abstract][Full Text] [Related]
32. How lenalidomide is changing the treatment of patients with multiple myeloma.
Dimopoulos MA; Terpos E; Niesvizky R
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
[TBL] [Abstract][Full Text] [Related]
33. Persistent malignant stem cells in del(5q) myelodysplasia in remission.
Tehranchi R; Woll PS; Anderson K; Buza-Vidas N; Mizukami T; Mead AJ; Astrand-Grundström I; Strömbeck B; Horvat A; Ferry H; Dhanda RS; Hast R; Rydén T; Vyas P; Göhring G; Schlegelberger B; Johansson B; Hellström-Lindberg E; List A; Nilsson L; Jacobsen SE
N Engl J Med; 2010 Sep; 363(11):1025-37. PubMed ID: 20825315
[TBL] [Abstract][Full Text] [Related]
34. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
36. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Popat U; Saliba R; Thandi R; Hosing C; Qazilbash M; Anderlini P; Shpall E; McMannis J; Körbling M; Alousi A; Andersson B; Nieto Y; Kebriaei P; Khouri I; de Lima M; Weber D; Thomas S; Wang M; Jones R; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2009 Jun; 15(6):718-23. PubMed ID: 19450756
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Kumar SK; Lacy MQ; Hayman SR; Stewart K; Buadi FK; Allred J; Laumann K; Greipp PR; Lust JA; Gertz MA; Zeldenrust SR; Bergsagel PL; Reeder CB; Witzig TE; Fonseca R; Russell SJ; Mikhael JR; Dingli D; Rajkumar SV; Dispenzieri A
Am J Hematol; 2011 Aug; 86(8):640-5. PubMed ID: 21630308
[TBL] [Abstract][Full Text] [Related]
38. Treatment of newly diagnosed multiple myeloma.
Palumbo A; Magarotto V; Larocca A; Bringhen S; Falco P; Di Raimondo F; Baldini L; Boccadoro M
Curr Hematol Malig Rep; 2008 Apr; 3(2):107-14. PubMed ID: 20425454
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide.
Weisel K; Kanz L
Recent Results Cancer Res; 2014; 201():347-57. PubMed ID: 24756803
[TBL] [Abstract][Full Text] [Related]
40. Treatment of plasma cell dyscrasias with lenalidomide.
Dimopoulos MA; Kastritis E; Rajkumar SV
Leukemia; 2008 Jul; 22(7):1343-53. PubMed ID: 18509355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
